CervoMed Inc. - Common Stock CRVO 深 沪
已收盘 10-17 16:00:00 美东时间
7.08
-0.520
-6.84%
华盛通- 最 高7.6199
- 今 开7.60
- 成交量 12.49万股
- 最 低 7.03
- 昨 收 7.60
- 总市值 6550.91万
- 52周最高 16.94
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.80
- 委 比 -99.31%
- 总股本 925.27万
- 历史最高 17437.50
- 量 比 1.49
- 振 幅 7.76%
- 历史最低 1.80
- 每 手 1
- 风险率 3.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多【天风医药杨松团队|首次覆盖】康弘药业：眼科药物龙头企业，肿瘤药研发塑造第二成长曲线
（来源：一棵大松树） 康弘药业成立于1996年，业务领域覆盖生物制品、中成药、化学药及医疗器械研发、生产、销售及售后服务，拥有先进的研发中心和标...
10-14 13:00
石药集团siRNA降脂新药在美国获批临床 | 1分钟药闻速览
医线药闻10月9日，石药集团（1093.HK）宣布，本集团自主研发的化学1类新药SYH2070注射液（双链小干扰RNA（siRNA）药物）已获得美国食品药品监督...
10-11 11:06
CervoMed Shares Additional Data From Phase 2b RewinD-LB Trial, Further Demonstrating Neflamapimod's Potential For Dementia With Lewy Bodies
Significant improvement relative to placebo on primary outcome measure, change in Clinical Dementia Rating Sum of Boxes (CDR-SB), demonstrated in a within-subject analysis in participants with low likelihood of having
10-08 19:03
CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies
CervoMed's Phase 2b RewinD-LB trial shows significant improvement in CDR-SB scores and reduction in GFAP biomarker levels in DLB patients with low AD co-pathology likelihood. Participants transitioning from placebo to neflamapimod B showed notable clinical benefits, with a 75% risk reduction in disease progression. The company expects FDA feedback on Phase 3 trial design by Q4 2025.
10-08 11:00
CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer
CervoMed Inc. announced the appointment of Matthew Winton, Ph.D., as Chief Commercial and Business Officer, bringing nearly 20 years of biotech industry experience. This move aims to prepare for late-stage development and market readiness of neflamapimod, a potential treatment for dementia with Lewy bodies. Dr. Winton’s expertise in commercialization and leadership in neurology treatments positions CervoMed for growth and innovation.
10-07 12:00
CervoMed Highlights Dementia Drug Results at Major Neurology Conference
CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that the promising development program and potential
09-17 19:42
CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference
CervoMed Inc. announced that neflamapimod, a potential treatment for Dementia with Lewy Bodies (DLB), was highlighted at the 150th Annual American Neurological Association conference. Neflamapimod showed promising results in reducing the risk of disease worsening in a Phase 2b trial, with a 74% risk reduction compared to placebo in patients with pure DLB. The company is preparing for a Phase 3 trial, aiming to align with the FDA by year-end 2025....
09-17 11:30
HC Wainwright & Co. Reiterates Neutral on CervoMed, Announces $11 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Neutral and announces $11 price target.
09-08 18:55
CervoMed to Participate in Upcoming Investor Conferences
CervoMed Inc. announced that its management will participate in two investor conferences in September 2025: the H.C. Wainwright 27th Annual Global Investment Conference on September 8, featuring a presentation and 1x1 investor meetings, and Morgan Stanley's 23rd Annual Global Healthcare Conference from September 8-10, focusing on 1x1 investor meetings. CervoMed, a clinical-stage company developing treatments for age-related neurologic disorders, ...
09-03 12:00
D. Boral Capital Maintains Buy on CervoMed, Raises Price Target to $31
D. Boral Capital analyst Jason Kolbert maintains CervoMed (NASDAQ:CRVO) with a Buy and raises the price target from $15 to $31.
08-18 19:45
